63981-33-9

Basic information

• Product Name: 1-Methyl-3-propyl-6-aminouracil
• Synonyms: 1-Methyl-3-propyl-6-aminouracil;6-Amino-1-methyl-3-propyluracil
• CAS NO: 63981-33-9
• Molecular Formula: C₈H₁₃N₃O₂
• Molecular Weight: 183.2077
• Mol File: 63981-33-9.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 275.9°Cat760mmHg
• Flash Point: 120.6°C
• Appearance: /
• Density: 1.185g/cm³
• Vapor Pressure: 0.00496mmHg at 25°C
• Refractive Index: 1.529
• CAS DataBase Reference: 1-Methyl-3-propyl-6-aminouracil(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Methyl-3-propyl-6-aminouracil(63981-33-9)
• EPA Substance Registry System: 1-Methyl-3-propyl-6-aminouracil(63981-33-9)

Safety Data

• Hazardous Substances Data: 63981-33-9(Hazardous Substances Data)

Usage

InChI:InChI=1/C8H13N3O2/c1-3-4-11-7(12)5-6(9)10(2)8(11)13/h5H,3-4,9H2,1-2H3

Upstream product

• 2434-53-9 6-amino-1-methyluracil 
• 107-08-4 1-iodo-propane 
• 342644-44-4 (E)-N,N-dimethyl-N'-(3-methyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)formimidamide 
• 1055300-49-6 6-[1-aza-2-(dimethylamino)vinyl]-1-methyl-3-propyl-1,3-dihydropyrimidine-2,4-dione 
• 6972-77-6 N-cyanoacetyl-N'-methyl-urea 
• 341487-54-5 6-[1-aza-2-(dimethylamino)vinyl]-1-methyl-1,3-dihydropyrimidine-2,4-dione 
• 341487-55-6 N'-(1,2,3,6-tetrahydro-3-methyl-2,6-dioxo-1-propylpyrimidin-4-yl)-N,N-dimethylformamidine 

Downstream Products

• 1228384-77-7 6-amino-5-{[(4-cyclopentyloxy)-3-methoxybenzylidene]amino}-1-methy-3-propylluracil 
• 1228384-78-8 8-[4-(cyclopentyloxy)-3-methoxyphenyl]-3-methyl-1-propylxanthine 
• 116545-95-0 8-(4-Cyanophenyl)-3-methyl-1-n-propylxanthine 
• 132940-23-9 8-(4-Hydroxy-phenyl)-3-methyl-1-propyl-3,7-dihydro-purine-2,6-dione 
• 132940-50-2 4-{[(E)-6-Amino-1-methyl-2,4-dioxo-3-propyl-1,2,3,4-tetrahydro-pyrimidin-5-ylimino]-methyl}-benzonitrile 
• 132940-72-8 (E)-N-(6-Amino-1-methyl-2,4-dioxo-3-propyl-1,2,3,4-tetrahydro-pyrimidin-5-yl)-3-phenyl-acrylamide 
• 132940-43-3 trans-3-methyl-8-(2-phenylethenyl)-1-n-propylxanthine 
• 106686-66-2 8-Cyclohexyl-1,3-dipropylxanthine 
• 132940-47-7 6-Amino-5-{[1-(4-hydroxy-phenyl)-meth-(E)-ylidene]-amino}-1-methyl-3-propyl-1H-pyrimidine-2,4-dione 
• 132940-65-9 Cyclohexanecarboxylic acid (6-amino-2,4-dioxo-1,3-dipropyl-1,2,3,4-tetrahydro-pyrimidin-5-yl)-amide 
• 129366-44-5 3-methyl-8-phenyl-1-n-propylxantine 
• 132940-66-0 Cyclohexanecarboxylic acid (6-amino-1-methyl-2,4-dioxo-3-propyl-1,2,3,4-tetrahydro-pyrimidin-5-yl)-amide 
• 132940-45-5 6-Amino-1-methyl-5-{[1-phenyl-meth-(E)-ylidene]-amino}-3-propyl-1H-pyrimidine-2,4-dione 
• 132940-37-5 8-Cyclohexyl-3-methyl-1-propyl-3,7-dihydro-purine-2,6-dione 

Relevant articles and documents

Synthesis and lipid-lowering evaluation of 3-methyl-1 H-purine-2,6-dione derivatives as potent and orally available anti-obesityagents

Obesity accompanied with metabolic disorder is often complicated with a strong link of dyslipidemia and insulin resistance, whose indicator is the excess accumulation of triglycerides (TG) in cells. Consideration the idea of lipid-lowering and improving insulin resistance, 34 novel compounds by combination the xanthine scaffold with the chain of Rosiglitazone have been synthesized. Among them, several compounds showed efficiency on reducing TG in 3T3-L1 adipoctyes, and 11c exhibited the most optimal capacity in lipid-lowering and improving obese clinical symptoms in DIO mice. Furthermore, the hydrochloride of 11c (11c·HCl) showed excellent bioavailability, 58.94%, over 2 folds than that (28.03%) of 11c, and the anti-obesity effect of 11c·HCl at 50 mg/kg dose was better than that of Metformin at 150 mg/kg dose in DIO mice, almost reversed HFD to a normal level. Thus, 11c·HCl might be a potent and orally available anti-obesity agent via alleviating the obese clinical symptoms, body fat, improving serum parameters and insulin resistance and TG clearance in liver.

Discovery of a novel A2B adenosine receptor antagonist as a clinical candidate for chronic inflammatory airway diseases

Recently, we have reported a series of new 1,3-symmetrically (R1 = R3) substituted xanthines (3 and 4) which have high affinity and selectivity for the human adenosine A2B receptors (hA 2B-AdoR). Unfortunately, this class of compounds had poor pharmacokinetic properties. This prompted us to investigate the effect of differential alkyl substitution at the N-1 and N-3 positions (N1-R ≠ N3-R) on A2B-AdoR affinity and selectivity; we had the dual objectives of enhancing affinity and selectivity for the A 2B-AdoR, as well as improving oral bioavailability. This effort has led to the discovery of compound 62, that displayed high affinity and selectivity for the hA2B-AdoR (Ki = 22 nM). In addition, compound 62 showed high functional potency in inhibiting the accumulation of cyclic adenosine monophosphate induced by 5′-N-ethylcarboxamidoadenosine in HEK-A2B-AdoR and NIH3T3 cells with KB values of 6 and 2 nM, respectively. In a single ascending-dose phase I clinical study, compound 62 had no serious adverse events and was well tolerated.

A2B adenosine receptor antagonists

Disclosed are novel compounds that are A2B adenosine receptor antagonists, useful for treating various disease states, including asthma and diarrhea.